BCAX
Bicara Therapeutics·NASDAQ
--
--(--)
--
--(--)
4.36 / 10
Netural
Fund flow evaluation: 7.8/10 reflecting robust fund flow characteristics. Constructive Small trends face headwinds from adverse overall, block, Medium, Large, and Extra-large developments, indicating positive money flow direction. Analyst consensus points to overwhelmingly bullish analyst consensus with strong conviction. Distribution analysis: Buy(100.0%) among 2 research opinions, supported by 0.92 historical weighted rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-13
InstitutionWedbush
Times predicted3
Historical Win Rate33.3%
Is money flowing into or out of BCAX?
- BCAX holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 4.36/10 (Netural).
